An Open-Label Extension Study With REQUIP (Ropinirole) CR for Subjects From Studies 101468/165, 101468/168 and 101468/169.
Phase of Trial: Phase III
Latest Information Update: 27 Mar 2017
At a glance
- Drugs Ropinirole (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational
- Sponsors GlaxoSmithKline
- 22 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Oct 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 24 Feb 2010 Additional trial location [Spain] identified as reported by ClinicalTrials.gov.